Keine Story von AstraZeneca Pharmaceuticals LP mehr verpassen.

AstraZeneca Pharmaceuticals LP

  • 09.11.2008 – 15:06

    CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study

    New Orleans, November 9 (ots/PRNewswire) - New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a ...